EyeGate sees $15 million in new funding

EyeGate Pharmaceuticals Inc., a small speciality drug company in Waltham, said today that it raised $15 million in a new round of venture capital, bringing its total venture funding to $31 million.

Investors in the company include Medicis Capital, Ventech, Innoven Partenaires and the Nexus Group. Eyegate said it plans to use the latest funds to launch two mid-stage clinical trials for a steroid treatment for eye inflammation and dry eye.
(By Todd Wallack, Globe staff)

•  Previous Entry
• Next Entry